S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:PBLA

Panbela Therapeutics (PBLA) Stock Price, News & Analysis

$0.67
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.60
$0.69
50-Day Range
$0.56
$6.87
52-Week Range
$0.41
$477.00
Volume
92,549 shs
Average Volume
264,921 shs
Market Capitalization
$2.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$500.00

Panbela Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
74,526.9% Upside
$500.00 Price Target
Short Interest
Healthy
2.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.60mentions of Panbela Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($63.80) to ($55.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.21 out of 5 stars

PBLA stock logo

About Panbela Therapeutics Stock (NASDAQ:PBLA)

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

PBLA Stock Price History

PBLA Stock News Headlines

Recap: Panbela Therapeutics Q4 Earnings
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Earnings Preview: Panbela Therapeutics
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
PBLA Panbela Therapeutics, Inc.
Panbela Therapeutics Inc (PBLA)
Panbela Therapeutics Prices $9 Mln Share Offering
Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?
See More Headlines
Receive PBLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Panbela Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/26/2024
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PBLA
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$500.00
High Stock Price Target
$500.00
Low Stock Price Target
$500.00
Potential Upside/Downside
+74,526.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-34,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4,607.33) per share

Miscellaneous

Free Float
3,477,000
Market Cap
$2.33 million
Optionable
Not Optionable
Beta
1.54
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Jennifer K. Simpson CRNP (Age 56)
    M.S.N., Ph.D., CEO, President & Director
    Comp: $527k
  • Ms. Susan Horvath (Age 65)
    VP of Finance, CFO, Secretary & Treasurer
    Comp: $333k
  • Ms. Tammy Groene
    Vice President of Operations
  • Dr. Elizabeth Bruckheimer Ph.D.
    VP & Chief Scientific Officer

PBLA Stock Analysis - Frequently Asked Questions

Should I buy or sell Panbela Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Panbela Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBLA shares.
View PBLA analyst ratings
or view top-rated stocks.

What is Panbela Therapeutics' stock price target for 2024?

2 equities research analysts have issued 12-month price targets for Panbela Therapeutics' stock. Their PBLA share price targets range from $500.00 to $500.00. On average, they anticipate the company's share price to reach $500.00 in the next year. This suggests a possible upside of 74,526.9% from the stock's current price.
View analysts price targets for PBLA
or view top-rated stocks among Wall Street analysts.

How have PBLA shares performed in 2024?

Panbela Therapeutics' stock was trading at $18.30 at the start of the year. Since then, PBLA stock has decreased by 96.3% and is now trading at $0.67.
View the best growth stocks for 2024 here
.

When is Panbela Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBLA earnings forecast
.

How were Panbela Therapeutics' earnings last quarter?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) posted its earnings results on Tuesday, March, 26th. The company reported ($65.90) EPS for the quarter, missing the consensus estimate of ($24.34) by $41.56.

When did Panbela Therapeutics' stock split?

Panbela Therapeutics's stock reverse split on Thursday, January 18th 2024. The 1-20 reverse split was announced on Thursday, January 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Panbela Therapeutics?

Shares of PBLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PBLA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners